ADC Bioanalysis Knowledge Base

ICH_M3R2_S6R1

7 min read

ICH M3(R2) + ICH S6(R1) — Nonclinical Study Timing & Biotech Safety (2009 + 2011)

概述 Overview

Two complementary ICH guidelines that define the nonclinical package for the antibody backbone of an ADC:

DocumentYearFocusSource
ICH M3(R2) — Nonclinical Safety Studies for Human Pharmaceuticals2009Timing of nonclinical studies relative to clinical developmenthttps://database.ich.org/sites/default/files/M3_R2__Guideline.pdf
ICH S6(R1) — Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals2011Study type, species selection, and design for biologicshttps://database.ich.org/sites/default/files/S6_R1_Guideline_0.pdf

Together, M3(R2) and S6(R1) define the regulatory framework for the antibody component of ADCs. The payload component falls under ICH S9. ADC programs must triangulate across S6(R1) + S9 + M3(R2) simultaneously.

核心要点 Key Points (M3 R2)

1. Study Timing Relative to Clinical Phases

M3(R2) provides a timing matrix — when each nonclinical study must be completed relative to Phase 1, 2, 3, and marketing authorization:

Study TypeBefore FIH (Phase 1)Before Phase 2Before Phase 3Before NDA/BLA
Single-dose tox (DRF)Recommended———
Repeat-dose (≥2 weeks)Required———
Repeat-dose (≥4 weeks, GLP)Required———
Repeat-dose (≥3 months, GLP)——Required—
Genotoxicity (Ames, in vitro CA)Required———
In vivo genotoxicity (MN)—Required——
Reproductive tox (fertility, EFD)—Phase 2b or beforeRequired—
Carcinogenicity———Required (except oncology)
Safety pharmacology (hERG, CNS, respiratory)Required———

ICH S9 exception: For advanced oncology indications, EFD is not required before Phase 2 (or Phase 3 if only treating patients with life-threatening cancer). Carcinogenicity not required at all.

2. Oncology Drug Exception (Refer to S9)

M3(R2) explicitly defers to ICH S9 for anticancer pharmaceuticals. Key exemptions:

  • Embryo-fetal developmental toxicity (EFD): not required before Phase 1 or 2
  • Carcinogenicity: not required (given anticancer indication)
  • Fertility: required before Phase 3 (or post-marketing for advanced settings)

3. Application to ADC Nonclinical Packages

Pre-IND package (IND-enabling) for an ADC:

  1. ≥4-week GLP repeat-dose toxicology in relevant species (monkey; rat if pharmacologically relevant)
  2. In vitro genotoxicity (Ames + chromosomal aberration/micronucleus) on:
    • The intact ADC
    • The free payload (often already genotoxic by mechanism — acceptable under S9)
  3. Safety pharmacology (hERG/cardiac + CNS + respiratory) on the intact ADC or antibody backbone; payload effects addressed separately if known
  4. Toxicokinetics (TAb, cAb, free payload) during tox studies

核心要点 Key Points (S6 R1)

1. Species Selection for Biologics

Principle: At least one pharmacologically relevant species must be used for safety testing. A pharmacologically relevant species is one in which:

  • The target antigen is expressed with similar affinity and tissue distribution as in humans
  • The biologic shows pharmacological activity (e.g., receptor binding or modulation) comparable to human

Implications for ADCs:

  • Cynomolgus monkey is pharmacologically relevant for most human cancer antigens (HER2, CD30, TROP-2, Nectin-4, BCMA)
  • Rat or mouse: often not relevant (many human tumor-associated antigens not expressed in rodent tissues or expressed at significantly different densities)
  • When no pharmacologically relevant non-human primate exists: consider transgenic rodent models or a homologous ADC surrogate with a rodent-specific antibody binding the murine orthologue

2. Immunogenicity in Nonclinical Studies

S6(R1) recognizes that human antibodies are immunogenic in non-human primates — the ADC antibody backbone will elicit anti-human-antibody (HAHA) responses in cynomolgus monkeys during multi-dose toxicology studies:

  • ADAs in monkey: Expected in multi-dose studies (typically develop after 2–4 doses)
  • Impact on tox study: ADA-positive animals may show accelerated ADC clearance and reduced systemic exposure → artificially reduced toxicity at doses where ADA develops
  • What to do: Monitor ADA at each dose cycle in tox animals; report ADA incidence in TK report; interpret tox endpoints in light of ADA status; may need to include ADA-positive animals in TK parameter calculation or report separately

ADA does not invalidate the study per S6(R1) — it is expected and must be documented, not a reason to repeat the study.

3. Tissue Cross-Reactivity (TCR)

S6(R1) requires tissue cross-reactivity studies for all biologic therapeutics:

  • Standard 37-tissue human panel (IHC with the therapeutic antibody)
  • Purpose: Identify unexpected antigen expression in normal human tissues → guides safety monitoring
  • Optional cynomolgus monkey TCR: to confirm relevance of species for safety extrapolation

ADC-specific TCR consideration: TCR uses the naked antibody (unconjugated) — identifies potential antigen-based off-target binding but does not capture Fc-mediated uptake by macrophages or other immune cells.

4. Duration of Repeat-Dose Studies

Clinical Trial PhaseRepeat-Dose Study Duration Required
Single-dose or 1-week exposure (Phase 1)2-week repeat-dose in relevant species
≤1 month clinical exposure1-month GLP (monkey), 1-month (rat if relevant)
≤3 months3-month GLP (monkey), 3-month (rat)
>6 months6-month GLP (monkey), 6-month (rat)
Lifetime (chronic)9-month GLP (monkey), 6-month (rat)

ADC practical note: Most Phase 1 oncology ADC trials allow dosing for many cycles (12+). A 4-week GLP monkey study suffices for IND filing; a 3-month study typically must be completed before Phase 3 initiation. Coordinate tox study completion timeline with Phase 1 dose escalation timeline.

常见问题和挑战，具体案例和解决方案

Challenge 1: Surrogate ADC for Rodent Studies — When Required?

Problem: Target antigen (e.g., HER2) is only expressed at low levels in rat. The intact clinical ADC shows no pharmacological activity in rat. How do you conduct rat toxicology?

S6(R1) answer: If rat is not pharmacologically relevant, a rat tox study is not required. However, FDA and EMA may request a rat surrogate ADC study if:

  1. The payload’s mechanism-based toxicity needs to be characterized in a second species (rodent)
  2. A known toxicity class effect (e.g., MMAE peripheral neuropathy) has not been well-characterized in monkey alone

Solution:

  1. Document pharmacological relevance assessment (antigen expression data in rat vs. monkey vs. human)
  2. If rat is not relevant: single monkey GLP study is sufficient per S6(R1)
  3. If rat is needed for payload characterization: use either the unconjugated payload (at equivalent doses) or a surrogate ADC using a rat-specific mAb conjugated to the same payload
  4. Consult FDA at pre-IND meeting to align on species requirement

Challenge 2: ADA Development in Monkey — When to Stop vs. Continue Dosing

Problem: In a 4-week GLP monkey study, 3/6 animals develop high-titer ADA by Week 3, with cAb AUC decreasing 10-fold relative to Day 1. Can the study continue? Can NOAEL be established?

S6(R1) guidance: ADA development does not automatically invalidate a repeat-dose study. Continue dosing; document ADA status, titer, and cAb exposure at each cycle. Interpret toxicity findings in the context of ADA status and exposure.

Solution:

  1. Separate toxicity analysis by ADA status: ADA− animals (full exposure) vs. ADA+ animals (reduced exposure)
  2. NOAEL is established from ADA− animals at the intended dose level
  3. ADA+ animals may show fewer toxicities (reduced exposure) — this is not necessarily protective; document and acknowledge
  4. Include ADA incidence and its impact on TK as limitations in the study report

Challenge 3: 3-Month Study Completion Before Phase 3 — Tight Timeline

Problem: Phase 1 dose escalation is complete and the sponsor wants to move directly to Phase 3 (accelerated approval pathway). The 3-month GLP monkey study was initiated but will not be complete in time.

S6(R1) / M3(R2) answer: Per M3(R2), 3-month repeat-dose studies must be completed before Phase 3 initiation. No exceptions under M3(R2). However:

Solution:

  1. Under ICH S9 (oncology flexibility): Phase 3 can initiate when the chronic toxicology study is ongoing if the 4-week study established NOAEL and there are no safety signals that predict harm from extended dosing
  2. Consult FDA and EMA at end-of-Phase-2 meeting — both agencies have granted Phase 3 initiation with a commitment to complete 3-month study before NDA/BLA (this is case-by-case)
  3. Risk-based argument: if Phase 1 showed no cumulative toxicity and Phase 2 has 12+ months of safety data, regulatory agencies may allow Phase 3 to proceed with the 3-month study as a commitment item

Graph View

Backlinks